Related Experiment Video
Updated: Apr 26, 2026
13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
8.5K
p21-activated kinase inhibitors.
Joachim Rudolph1, James J Crawford1, Klaus P Hoeflich2
1Genentech, Discovery Chemistry, South San Francisco, California, USA.
The Enzymes
|July 19, 2014
Summary
p21-activated kinases (PAKs) are crucial for cell functions and implicated in cancer. Developing selective PAK inhibitors is challenging, but allosteric inhibitors offer a promising therapeutic strategy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- p21-activated kinases (PAKs) are Ser/Thr kinases involved in cytoskeletal organization, cell migration, and signaling.
- PAKs are classified into Group I (PAK1-3) and Group II (PAK4-6) based on homology.
- PAK isoforms are frequently overexpressed in human cancers, suggesting their potential as therapeutic oncology targets.
Purpose of the Study:
- To explore the therapeutic utility of PAKs as oncology targets.
- To address the challenges in developing potent and kinome-selective ATP-competitive PAK inhibitors.
- To investigate allosteric inhibition as a strategy to overcome selectivity issues.
Main Methods:
- Review of in vitro and in vivo studies.
- Analysis of small-molecule tool compounds.
- Examination of ATP-competitive and allosteric inhibitor approaches.
Main Results:
- PAKs play significant roles in cellular processes and are implicated in various human cancers.
- Developing selective ATP-competitive PAK inhibitors is difficult due to the enzyme's ATP-binding site plasticity.
- Allosteric inhibitors, like IPA-3, targeting the Group I PAK autoregulatory domain show potential for selective inhibition.
Conclusions:
- PAKs represent viable oncology targets due to their roles in cancer.
- The plasticity of the PAK ATP-binding site poses challenges for selective inhibitor development.
- Allosteric inhibition offers a promising alternative strategy for developing selective PAK inhibitors, potentially evading challenges associated with ATP-competitive inhibitors.
Keywords:
ATP-competitive kinase inhibitorsAllosteric kinase inhibitorsGenomic amplificationKinase selectivityLigand efficiencyOncologyOverexpressionp21-activated kinasesMore Related Videos
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
8.9K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
10.9K
Related Concept Videos
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:34Inhibition of CDK Activity
4.3K
4.3K
01:22PI3K/mTOR/AKT Signaling Pathway
5.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.1K
02:15M-Cdk Drives Transition Into Mitosis
5.3K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K
01:20The JAK-STAT Signaling Pathway
10.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.1K
03:03mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K